Targets › CSF3
4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 3; Oncology, Other, Genitourinary; next expected readout Dec 2026.
Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes. (UniProt, P09919)
Open in Phaseline: the race on CSF3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| First Affiliated Hospital of Zhejiang University | Granulocyte colony-stimulating factor (G-CSF) G-CSF receptor agonist | CSF3 | Phase 3 | Healthy Hematopoietic Stem Cell Donor | Dec 2028 |
| Shandong University | Efbemalenograstim Alfa Granulocyte colony-stimulating factor (G-CSF) analog | CSF3 | Phase 2 | Ovarian Cancer | Dec 2026 |
| Fudan University | rhG-CSF + rhIL-11 Recombinant granulocyte-colony stimulating factor combined with recombinant interleukin-11 | CSF3, IL11 | Phase 2 | Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB) | Dec 2026 |
| Fakih IVF Fertility Center | Recombinant G-CSF Granulocyte colony-stimulating factor receptor agonist | CSF3 | Phase 2 | Recurrent Pregnancy Loss | Aug 2027 |
Ovarian Cancer (1) Healthy Hematopoietic Stem Cell Donor (1) Recurrent Pregnancy Loss (1) Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB) (1)
small molecule (3), protein or peptide (1)
Shandong University (1) First Affiliated Hospital of Zhejiang University (1) Fakih IVF Fertility Center (1) Fudan University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.